TLDR:
- BlossomHill Therapeutics, a new biotech company founded by J. Jean Cui, Ph.D., has raised $100 million in series B financing.
- The company aims to develop small molecule drugs for high-need cancers and autoimmune diseases to improve patient lives.
Article Summary:
A new biotech company, BlossomHill Therapeutics, has emerged with a $100 million funding to focus on developing small molecule drugs for various high-need cancers and autoimmune diseases. Founded by drug designer J. Jean Cui, Ph.D., the company plans to utilize proven drug design efforts to extend life expectancy and quality of life for patients. Cui, a successful biotech entrepreneur, previously formed Turning Point Therapeutics, which was later acquired by Bristol Myers Squibb for $4.1 billion. With a strong track record in developing FDA-approved cancer drugs, Cui now takes on the role of CEO at BlossomHill Therapeutics, with a team of experienced industry professionals also joining the company’s leadership. The funding will be used to advance the company’s pipeline and move its first two oncology programs into phase 1 trials, with additional preclinical programs in progress towards investigational new drug filings.
